- Home
- GGG vs EXEL Comparison
GGG vs EXEL Comparison
Compare GGG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GGG | EXEL |
|---|---|---|
| Founded | 1926 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GGG | EXEL |
|---|---|---|
| Price | $75.32 | $48.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $95.50 | $46.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.7M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 9.22 | ★ 57.95 |
| EPS | 0.70 | ★ 0.79 |
| Revenue | ★ $2,236,604,000.00 | $452,477,000.00 |
| Revenue This Year | $6.77 | $13.61 |
| Revenue Next Year | $4.86 | $13.13 |
| P/E Ratio | $107.59 | ★ $61.77 |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $74.65 | $33.76 |
| 52 Week High | $95.69 | $51.63 |
Technical Indicators
Market Signals| Indicator | GGG | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 57.98 |
| Support Level | N/A | $40.42 |
| Resistance Level | $84.14 | N/A |
| Average True Range (ATR) | 1.38 | 1.65 |
| MACD | -0.14 | 0.24 |
| Stochastic Oscillator | 10.35 | 67.90 |
Price Performance
Historical ComparisonAbout GGG Graco Inc.
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.2 billion in sales in 2025.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.